About: Advancements in DNA vaccine vectors, non-mechanical delivery methods, and molecular adjuvants to increase immunogenicity

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Advancements in DNA vaccine vectors, non-mechanical delivery methods, and molecular adjuvants to increase immunogenicity Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Advancements in DNA vaccine vectors, non-mechanical delivery methods, and molecular adjuvants to increase immunogenicity
Creator	Schmaljohn, Connie Suschak, John Williams, James
Source	Medline; PMC
abstract	A major advantage of DNA vaccination is the ability to induce both humoral and cellular immune responses. DNA vaccines are currently used in veterinary medicine, but have not achieved widespread acceptance for use in humans due to their low immunogenicity in early clinical studies. However, recent clinical data have re-established the value of DNA vaccines, particularly in priming high-level antigen-specific antibody responses. Several approaches have been investigated for improving DNA vaccine efficacy, including advancements in DNA vaccine vector design, the inclusion of genetically engineered cytokine adjuvants, and novel non-mechanical delivery methods. These strategies have shown promise, resulting in augmented adaptive immune responses in not only mice, but also in large animal models. Here, we review advancements in each of these areas that show promise for increasing the immunogenicity of DNA vaccines.
has issue date	2017-06-12(xsd:dateTime)
bibo:doi	10.1080/21645515.2017.1330236
bibo:pmid	28604157
has license	cc-by-nc-nd
sha1sum (hex)	6d04e85d2c994d73c9a7e2692af91470f407ddeb
schema:url	https://doi.org/10.1080/21645515.2017.1330236
resource representing a document's title	Advancements in DNA vaccine vectors, non-mechanical delivery methods, and molecular adjuvants to increase immunogenicity
has PubMed Central identifier	PMC5718814
has PubMed identifier	28604157
schema:publication	Hum Vaccin Immunother
resource representing a document's body	covid:6d04e85d2c994d73c9a7e2692af91470f407ddeb#body_text
is schema:about of	named entity 'DELIVERY METHODS' named entity 'DNA VACCINATION' named entity 'HERE' named entity 'HIGH' named entity 'WIDESPREAD' named entity 'REVIEW' named entity 'NOVEL' named entity 'BUT' named entity 'THESE' named entity 'INVESTIGATED' named entity 'IMMUNE RESPONSES' named entity 'VALUE' named entity 'IMPROVING' named entity 'USED' named entity 'ACCEPTANCE' named entity 'ESTABLISHED' named entity 'APPROACHES' named entity 'LEVEL' named entity 'AREAS' named entity 'INCREASING' named entity 'INCLUDING' named entity 'adjuvants' named entity 'vaccine efficacy' named entity 'However' named entity 'MICE' named entity 'VACCINE EFFICACY' named entity 'IMMUNOGENICITY' named entity 'DUE TO' named entity 'NON-' named entity 'STRATEGIES' named entity 'VECTOR' named entity 'RECENT' named entity 'ADAPTIVE IMMUNE RESPONSES' named entity 'DNA VACCINE' named entity 'MOLECULAR' named entity 'VECTORS' named entity 'NON-' named entity 'MECHANICAL' named entity 'TO INCREASE' named entity 'A MAJOR' named entity 'ANIMAL MODELS' named entity 'DNA VACCINES' named entity 'INCLUSION' named entity 'RESPONSES' named entity 'IMMUNOGENICITY' named entity 'EARLY' named entity 'LARGE' named entity 'PRIMING' named entity 'RESULTING IN' named entity 'VETERINARY MEDICINE' named entity 'PROMISE' named entity 'ANTIBODY' named entity 'DELIVERY METHODS' named entity 'AUGMENTED' named entity 'GENETICALLY ENGINEERED' named entity 'INDUCE' named entity 'ADJUVANTS' named entity 'CURRENTLY' named entity 'ADJUVANTS' named entity 'LOW' named entity 'THEIR' named entity 'USE' named entity 'DNA VACCINE' named entity 'HUMANS' named entity 'MECHANICAL' named entity 'CLINICAL STUDIES' named entity 'CLINICAL DATA' named entity 'CYTOKINE ' named entity 'DESIGN' named entity 'CELLULAR' named entity 'ADVANTAGE' named entity 'HAVE' covid:arg/6d04e85d2c994d73c9a7e2692af91470f407ddeb named entity 'areas' named entity 'augmented' named entity 'genetically engineered' named entity 'adaptive immune responses' named entity 'veterinary medicine' named entity 'adaptive immune responses'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software